Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis

  • Pierre Jacquet
  • Paul H. Sugarbaker
Part of the Cancer Treatment and Research book series (CTAR, volume 82)

Abstract

Productive research in patients with peritoneal carcinomatosis has moved slowly over several decades. In large part this was due to lack of standardized assessments by which cancer responses could be quantitated in a reliable and statistically evaluable manner. Recently, both laboratory and clinical assessments have been developed. Clinical research has shown that the prognosis of patients with peritoneal carcinomatosis is dependent upon preoperative and intraoperative variables [1]. These are the histologic grade of the malignancy, the preoperative tumor volume as assessed at surgery, the distribution of tumor at surgery, and the completeness of cytoreductive surgery. Also the preoperative abdominal and pelvic computed tomography (CT) scan has shown predictive value in assessment of the completeness of cytoreduction in patients with mucinous carcinomatosis [2]. The clinical research tools that are currently used in peritoneal carcinomatosis studies are reviewed in this manuscript.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancers with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg 1995,221:124–132.PubMedCrossRefGoogle Scholar
  2. 2.
    Jacquet P, Jelinek JS, Chang D, Sugarbaker PH. Abdominal CT scan in the selection of patients with peritoneal carcinomatosis for cytoreductive surgery. J Am Coll Surg 1995: in press.Google Scholar
  3. 3.
    Sugarbaker TA, Chang D, Koslowe P, Sugarbaker PH. Pathobiology of peritoneal carcinomatosis from ovarian malignancy. In Sugarbaker PH, ed. Peritoneal Carcinomatosis: Drugs and Diseases. Norwell, MA: Kluwer Academic Publishers, 1996, pp 63–73.CrossRefGoogle Scholar
  4. 4.
    Sugarbaker TA, Chang D, Koslowe P, Sugarbaker PH. Patterns of spread of recurrent intraabominal sarcoma. In Sugarbaker PH, ed. Peritoneal Carcinomatosis: Principles of Management. Norwell, MA: Kluwer Academic Publishers, 1996, pp 65–77.Google Scholar
  5. 5.
    Schellinx M, Von Meyenfeldt MF, Sugarbaker PH. Peritoneal carcinomatosis from adenocarcinoma of the colon. In Sugarbaker PH, ed. Peritoneal Carcinomatosis: Drugs and Diseases. Norwell, MA: Kluwer Academic Publishers, 1996, pp 247–261.CrossRefGoogle Scholar
  6. 6.
    Archer A. Radiology in the diagnosis of peritoneal carcinomatosis. In Sugarbaker PH, ed. Peritoneal Carcinomatosis: Diagnosis and Treatment. Norwell, MA: Kluwer Academic, 1995, pp ••-••Google Scholar
  7. 7.
    Jacquet P, Jelinek JS, Steves MA, Sugarbaker PH. Evaluation of computed tomography in patients with peritoneal carcinomatosis. Cancer 1993;72:1631–1636.PubMedCrossRefGoogle Scholar
  8. 8.
    Walkey MM, Friedman AC, Sohotra P, Radecki PD. CT manifestations of peritoneal carcinomatosis. AJR 1988;150:1035–1041.PubMedGoogle Scholar
  9. 9.
    Nelson RC, Chezmar JL, Hoel MJ, Buck DR, Sugarbaker PH. Peritoneal carcinomatosis: Preoperative CT with intraperitoneal contrast material. Radiology 1992;182:133–138.PubMedGoogle Scholar
  10. 10.
    Irimura T, Matsushita Y, Hoff SD, Yamori T, Nakamori S, et al. Ectopic expression of mucins in colorectal cancer metastasis. Semin Cancer Biol 1991;2:129–139.PubMedGoogle Scholar
  11. 11.
    Hayes DF, Silberstein DS, Rodrique SW, Kufe DW. DF3 antigen, a human epithelial mucin, inhibits adhesion of eosinophils to antibody-coated targets. J Immunol 1991;145:962.Google Scholar
  12. 12.
    Pihl E, Nairn RC, Hughes ES, Cuthbertson AM, Rollo AJ. Mucinous colorectal carcinoma: Immunopathology and prognosis. Pathology 1980;12:439–447.PubMedCrossRefGoogle Scholar
  13. 13.
    Halvorsen TB, Seim E. Influence of mucinous components on survival in colorectal adenocarcinomas: A multivariate analysis. J Clin Pathol 1988;41:1068–1072.PubMedCrossRefGoogle Scholar
  14. 14.
    Suma KS, Nirmala V. Mucinous component in colorectal carcinoma — Prognostic significance: A study in a south Indian population. J Surg Oncol 1992;51:60–64.PubMedCrossRefGoogle Scholar
  15. 15.
    Redman JR, Petroni GR, Saigo PE, et al. Prognostic factors in advanced ovarian carcinoma. J Clin Oncol 1986;4:515.PubMedGoogle Scholar
  16. 16.
    Chaitin BA, Gershenson DM, Evans HL. Mucinous tumors of the ovary. A clinic-opathologic study of 70 cases. Cancer 1985;55:1958–1962.PubMedCrossRefGoogle Scholar
  17. 17.
    Sugarbaker PH, Zhu BW, Sese GB, Shmookler B. Peritoneal carcinomatosis from appendiceal cancer: Results in 69 patients treated by cytoreductive surgery and intraperitoneal chemotherapy. Dis Colon Rectum 1993;36:323–329.PubMedCrossRefGoogle Scholar
  18. 18.
    Umpleby HC, Ranson DL, Williamson RC. Peculiarities of mucinous colorectal carcinoma. Br J Surg 1985;72:715–718.PubMedCrossRefGoogle Scholar
  19. 19.
    Symonds DA, Vickery AL. Mucinous carcinoma of the colon and rectum. Cancer 1976; 37:1891–1900.PubMedCrossRefGoogle Scholar
  20. 20.
    Minsky BD, Mies C, Rich TA, Recht A, Chaffey JT. Colloid carcinoma of the colon and rectum. Cancer 1987;60:3103–3112.PubMedCrossRefGoogle Scholar
  21. 21.
    Neutra MR, Forstner JF. Gastrointestinal mucus: Synthesis, secretion, and function. In Johnson LR, ed. Physiology of the Gastrointestinal Tract, 2nd ed. New York: Raven Press, 1987, pp 975–1009.Google Scholar
  22. 22.
    Almagro UA. Primary signet ring carcinoma of the colon. Cancer 1983;52:1453–1457.PubMedCrossRefGoogle Scholar
  23. 23.
    Giacchero A, Aste H, Barrachini P, Conio MR, et al. Primary signet ring carcinoma of the large bowel: Report of nine cases. Cancer 1985;56:2723.Google Scholar
  24. 24.
    Sugarbaker PH. Cancer of the appendix and pseudomyxoma. In Fazio VW, ed. Current Therapy in Colon and Rectal Surgery. Philadelphia: BC Decker, 1989, pp 295–301.Google Scholar
  25. 25.
    Young RC, Perez CA, Hoskins WJ. Cancer of the ovary. In De Vita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 4th ed. Philadelphia: JB Lippincott, 1993, pp 1226–1262.Google Scholar
  26. 26.
    Minsky BD. Clinicopathologic impact of colloid in colorectal carcinoma. Dis Colon Rectum 1990;33:714–719.PubMedCrossRefGoogle Scholar
  27. 27.
    Sugarbaker PH. Pseudomyxoma Peritonei. A cancer whose biology is characterized by a redistribution phenomenom. Ann Surg 1994;219:109–111.PubMedCrossRefGoogle Scholar
  28. 28.
    Zahn CM, Shmookler BM, Sugarbaker PH. Pseudomyxoma peritonei: A proposed grading system. In progress.Google Scholar
  29. 29.
    Sugarbaker PH. Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology. In Sugarbaker PH, ed. Peritoneal Carcinomatosis: Diagnosis and Treatment. Norwell, MA: Kluwer Academic Publishers, 1995, pp 79–100.Google Scholar
  30. 30.
    Sugarbaker PH. Peritoneal carcinomatosis from large bowel and appendiceal cancer: A new approach to treatment. Postgrad Adv Colorectal Surg 1991;11-X:1–14.Google Scholar
  31. 31.
    Los G, Mc Vie JG. Experimental and clinical status of intraperitoneal chemotherapy. Eur J Cancer 1990;26:755–762.PubMedCrossRefGoogle Scholar
  32. 32.
    Averbach AM, Sugarbaker PH. Recurrent intraabdominal cancer causing intestinal obstruction. Int Surg 1995: in press.Google Scholar
  33. 33.
    Vassilopoulos PP, Ledesma EJ, Yoon JM, Jung O, Mittelman A. Surgical treatment of metastatic colorectal adenocarcinoma. Dis Colon Rectum 1981;24:265–271.PubMedCrossRefGoogle Scholar
  34. 34.
    Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. NCI Monogr 1975;42.T01.Google Scholar
  35. 35.
    Hacker NF, Berek JS, Lagasse LD, et al. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 1983;61:413.PubMedGoogle Scholar
  36. 36.
    Piver MS, Lele SB, Marchetti DL, et al. The impact of aggressive debulking surgery and cisplatin chemotherapy on Progression-free survival in stage III and IV ovarian carcinoma. J Clin Obstet Gynecol 1988;6:983.Google Scholar
  37. 37.
    Cunliffe WJ, Sugarbaker PH. Gastrointestinal malignancy: Rationale for adjuvant therapy using early postoperative intraperitoneal chemotherapy. Br J Surg 1989;76:1082–1090.PubMedCrossRefGoogle Scholar
  38. 38.
    Sugarbaker PH. Intraperitoneal chemotherapy for treatment and prevention of peritoneal carcinomatosis and Sarcomatosis. Dis Colon Rectum 1994;37(Suppl):S115–S122.PubMedCrossRefGoogle Scholar
  39. 39.
    Markman M. Intraperitoneal therapy for treatment of malignant disease principally confined to the peritoneal cavity. Crit Rev Oncol Hematol 1993;14:15–28.PubMedCrossRefGoogle Scholar
  40. 40.
    Kerr DJ, Kaye SB. Aspects of cytotoxic drug penetration with particular reference to anthracyclines. Cancer Chemother Pharmacol 1987;9:1–5.CrossRefGoogle Scholar
  41. 41.
    Los G, Smals OA, Van Vight MJ. A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity. Cancer Res 1992;52:1252–1258.PubMedGoogle Scholar
  42. 42.
    Ozols RF, Locker GY, Doroshow JH, et al. Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res 1979;39:3209–3214.PubMedGoogle Scholar
  43. 43.
    Maguire RT, Schmelter RF, Pascucci VL, Conklin JJ. Immunoscintigraphy of colorectal adenocarcinoma: Results with site-specifically radiolabeled B72.3 (111In-CYT-103). Antibody Immunoconj Radiopharma 1989;2:257–269.Google Scholar
  44. 44.
    Colcher D, Horan Hand P, Nuti M, Scholm J. A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc Natl Acad Sci USA 1981;18:3199–3203.CrossRefGoogle Scholar
  45. 45.
    Scholm J. Basic principles and applications of monoclonal antibodies in the management of carcinomas. The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1986;46:3225–3238.Google Scholar
  46. 46.
    Thor A, Ohuchi N, Szpak CA, Johnston WW, Scholm J. The distribution of oncofetal antigen TAG-72 defined by monoclonal antibody B72.3. Cancer Res 1986;46:3118–3124.PubMedGoogle Scholar
  47. 47.
    Doerr RJ, Abdel-Nabi H, Krag D, Mitchell E. Radiolabeled antibody imaging in the management of colorectal cancer: Results of a multicenter clinical study. Ann Surg 1991; 214:118–124.PubMedCrossRefGoogle Scholar
  48. 48.
    Collier BD, Abdel-Nabi H, Doerr RJ, Harwood SJ, Olsen J, et al. Immunoscintigraphy performed with In-11-labeled CYT-103 in the management of colorectal cancer: Comparison with CT. Radiology 1992;185:179–186.PubMedGoogle Scholar
  49. 49.
    Martin EW, Hinckle GH, Tuttle S, et al. Intraoperative radioimmunodetection of colorectal tumor with hand-held radiation detector. Am J Surg 1985;50:672–675.CrossRefGoogle Scholar
  50. 50.
    Kim JA, Triozzi PL, Martin EW. Radioimmunoguided surgery for colorectal cancer. Oncology 1993;7:55–64.PubMedGoogle Scholar
  51. 51.
    Molino A, Simpson JF, Thor A, et al. Enhanced tumor binding using immunohistochemical analyses by the second generation antitumor associated glycoprotein 72 monoclonal antibodies versus monoclonal antibody B72.3 in human tissue. Cancer Res 1990;50: 1291–1298.Google Scholar
  52. 52.
    Arnold MW, Schneebaum S, Berens A, Mojzisik C, Hinkle G, Martin EW. Radioimmunoguided surgery challenges traditional decision making in patients with primary colorectal cancer. Surgery 1992;112:624–630.PubMedGoogle Scholar
  53. 53.
    Arnold MW, Schneebaum S, Berens A, Petty L, Mojzisik C, Hinkle G, Martin EW. Intraoperative detection of colorectal cancer with radioimmunoguided surgery and CC49, a second generation monoclonal antibody. Ann Surg 1992;216:627–632.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers, Boston 1996

Authors and Affiliations

  • Pierre Jacquet
  • Paul H. Sugarbaker

There are no affiliations available

Personalised recommendations